Regulatory tracker: FDA accepts Roche's application for Lunsumio-Polivy combo
• The FDA has accepted Roche's application to use the combination of Lunsumio and Polivy for patient treatment. • This regulatory milestone is part of Roche's effort to expand the indications and clinical utility of these existing in-market products. • The development matters as it potentially provides a new therapeutic option for patients requiring this specific drug combination.
fiercepharma.com




